An Unusual Case of Metastatic Basal Cell Carcinoma of the Prostate: A Case Report and Literature Review

Dong, Shiqiang; Liu, Qing; Xu, Zihan; Wang, Haitao

doi:10.3389/fonc.2020.00859

Cited by 12 publications

(20 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, Dong et al . reported that a 62‐year‐old man with BCC showed multiple lung metastases 2 years after radical prostatectomy and adjuvant radiation 8 . The current 80‐year‐old patient showed 5% of Ki‐67 labeling index without other prostate malignant component and evident distant metastases so that we undertake no adjuvant radical treatment but close follow‐up.…”

Section: Discussionmentioning

confidence: 87%

Basal cell carcinoma of the prostate diagnosed incidentally with holmium laser enucleation of the prostate: How can we detect prior to benign prostatic hyperplasia surgery?

Ohara¹,

Aoki²,

Arakawa³

et al. 2021

IJU Case Reports

View full text Add to dashboard Cite

Introduction Basal cell carcinoma of the prostate is a rare prostate malignancy. Its diagnosis and treatment have not been well established yet. Case presentation An 80‐year‐old man was referred to our hospital for undergoing holmium laser enucleation of the prostate with persistent lower urinary tract symptoms. Ultrasonography showed enlarged prostate (41.3 cc) with mid‐lobe hypertrophy. His prostate‐specific antigen and testosterone levels were 0.437 ng/mL and 873 ng/dL, respectively. Histological examination of the enucleated tissue confirmed basal cell carcinoma. The cells were positive for bcl‐2, 34βE12, p63, and cytokeratin 5/6. Ki‐67 labeling index was 5%. Subsequent staging computed tomography scan and bone scintigram showed neither lymph node nor distant metastasis. Currently, the patient is under close follow‐up with imaging, endoscopy, and urodynamic study. Conclusion It is difficult for physicians to detect prostate basal cell carcinoma before benign prostatic hyperplasia surgery. In case of organ‐confined disease, age and Ki‐67 labeling index could be suggestive of subsequent treatment decision‐making.

show abstract

Section: Discussionmentioning

confidence: 87%

Basal cell carcinoma of the prostate diagnosed incidentally with holmium laser enucleation of the prostate: How can we detect prior to benign prostatic hyperplasia surgery?

Ohara¹,

Aoki²,

Arakawa³

et al. 2021

IJU Case Reports

View full text Add to dashboard Cite

show abstract

“…Contrary to adenocarcinoma of the prostate, BCCs tend to metastasize viscerally to the liver, lung and bowel. Out of the 17 patients with advanced BCC of the prostate, 64.7% were diagnosed with liver metastasis [7,8 ▪ ,9–12].…”

Section: Review Of the Current Literaturementioning

confidence: 99%

Basal cell carcinoma of the prostate: a case report responding to the FGFR inhibitor pemigatinib and literature review

Rebhan

Wasinger

Hassler

et al. 2022

Current Opinion in Urology

View full text Add to dashboard Cite

Purpose of reviewDue to the limited number of cases, there are no guidelines for basal cell carcinoma (BCC) of the prostate. This review combines an unpublished case report of a 55-year-old patient with BCC with an assessment of the latest literature.Recent findingsBCC of the prostate has previously been described in only approximately 140 cases. We describe the diagnostic process, including the uropathological and DNA-sequencing results, which allowed us to start an experimental treatment with pemigatinib. BCC of the prostate is associated with an aggressive biological and clinical behavior, such as recurrence and metastasis. Several immunohistochemical stainings are available to differentiate BCC from adenocarcinoma of the prostate. Based on pathology and results from next-generation sequencing (NGS), patients can be offered targeted therapies.SummaryWith the aid of histological work-up and immunostaining, prostatic BCC can be accurately diagnosed. Our patient underwent radical prostatectomy and staged extended lymphadenectomy due to lymph node recurrence. The patient subsequently developed progressive disease and was treated with the FGFR-inhibitor pemigatinib. The patient's liver metastasis significantly responded. The present case confirms the possibility of aggressive behavior of prostatic BCC and highlights the importance of a thorough uropathological and molecular biological analysis with a precision medicine strategy.

show abstract

“…The first case of BCCP was reported in 1974, and the total cumulativenumber of reported cases till date is about 140 ( 8 , 9 ). BCCP is usually considered to be insidious, but there are many reported cases of recurrence and metastasis ( 4 , 10 ). About 44% and 10% of patients experience recurrence and death due to metastasis, respectively ( 5 ).…”

Section: Discussionmentioning

confidence: 99%

Basal cell carcinoma of the prostate with squamous metaplasia: A case report and literature review

Wang

Zhang²,

Chen³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Basal cell carcinoma of the prostate (BCCP) is a rare tumor with a total incidence of 140 cases to date. However, BCCP with squamous metaplasia has not been reported as of date. In this paper, we report the first case of BCCP with squamous metaplasia. The patient was hospitalized for progressive dyspareunia and had been treated for recurrent urinary retention four times in 5 years. Rectal examination showed that the prostate was medium in texture with no palpable nodules. The levels of total prostate specific antigen (tPSA), free prostate specific antigen (fPSA), and fPSA/tPSA (f/t) ratio were 1.29 ng/mL, 0.4 ng/mL, and 0.31, respectively. Ultrasound of the urinary tract showed that the prostate gland was 51 mm*40 mm*38 mm in size. We performed transurethral resection of the prostate. Histopathology confirmed the diagnosis of basal cell carcinoma with focal squamous differentiation, and immunohistochemical staining was positive for P63 and 34βE12. A laparoscopic radical prostatectomy was performed 45 days after the first surgery and the postoperative pathology showed a small amount of residual tumor with negative margins and no involvement of the seminal vesicles and vas deferens. The patient was followed up for 50 months and was doing well by the end of our study. We describe the clinical symptoms, pathological features, treatment, and prognosis of patients with BCCP with squamous metaplasia. The relevant published literature is also briefly reviewed.

show abstract

An Unusual Case of Metastatic Basal Cell Carcinoma of the Prostate: A Case Report and Literature Review

Cited by 12 publications

References 24 publications

Basal cell carcinoma of the prostate diagnosed incidentally with holmium laser enucleation of the prostate: How can we detect prior to benign prostatic hyperplasia surgery?

Basal cell carcinoma of the prostate diagnosed incidentally with holmium laser enucleation of the prostate: How can we detect prior to benign prostatic hyperplasia surgery?

Basal cell carcinoma of the prostate: a case report responding to the FGFR inhibitor pemigatinib and literature review

Basal cell carcinoma of the prostate with squamous metaplasia: A case report and literature review

Contact Info

Product

Resources

About